Trial Profile
Randomized, double-blind, placebo-controlled trial of the safety and efficacy of MP03-36 in subjects with seasonal allergic rhinitis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Apr 2015
Price :
$35
*
At a glance
- Drugs Azelastine (Primary)
- Indications Seasonal allergic rhinitis
- Focus Therapeutic Use
- Sponsors Meda Pharmaceuticals
- 16 Nov 2010 Results were presented at the 2010 Annual Meeting of the American College of Allergy, Asthma and Immunology.
- 01 Oct 2009 Results reported in the Allergy and Asthma Proceedings.
- 17 Mar 2009 Results presented at AAAAI